| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025961711 |
| P356 | DOI | 10.1007/S00280-015-2951-0 |
| P698 | PubMed publication ID | 26707728 |
| P2093 | author name string | Lei Hu | |
| Wei Zhuo | |||
| Hong-Hao Zhou | |||
| Lan Fan | |||
| Cong-Min Zhang | |||
| Jin-Feng Lv | |||
| P2860 | cites work | Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer | Q24309649 |
| A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 | ||
| Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF | Q24609040 | ||
| MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer | Q24645663 | ||
| MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 | Q24648241 | ||
| The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores | Q24649374 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide | Q27853156 | ||
| Chromatin modifications and their function | Q27861067 | ||
| Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer | Q28242111 | ||
| MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents | Q28244659 | ||
| Histone methylation: a dynamic mark in health, disease and inheritance | Q28263573 | ||
| miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells | Q28278471 | ||
| Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway | Q28539122 | ||
| Cancer epigenetics: from mechanism to therapy | Q29614799 | ||
| The history of cancer epigenetics | Q29617273 | ||
| Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer | Q31022382 | ||
| Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma | Q33520339 | ||
| MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. | Q33575825 | ||
| Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. | Q33711106 | ||
| Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. | Q33728760 | ||
| DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response | Q33816178 | ||
| miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer | Q34407238 | ||
| Pharmacogenomics: the inherited basis for interindividual differences in drug response | Q34433440 | ||
| MicroRNAs in cell proliferation, cell death, and tumorigenesis. | Q34497050 | ||
| Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer | Q34513935 | ||
| Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation | Q34618963 | ||
| Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. | Q34798833 | ||
| Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer | Q34998307 | ||
| Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. | Q35034638 | ||
| Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia | Q35051430 | ||
| MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. | Q35053331 | ||
| Novel and emerging targeted-based cancer therapy agents and methods | Q35558057 | ||
| Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. | Q35605072 | ||
| ABCG2 expression, function, and promoter methylation in human multiple myeloma | Q35848835 | ||
| Clinical utility of RASSF1A methylation in human malignancies | Q35909621 | ||
| Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. | Q35919726 | ||
| Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel | Q36460311 | ||
| Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. | Q36809577 | ||
| Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. | Q36913739 | ||
| Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts | Q37027202 | ||
| Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients | Q37394399 | ||
| Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma | Q37425078 | ||
| Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics | Q37799682 | ||
| The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations | Q37815545 | ||
| Epigenomics and interindividual differences in drug response | Q38055065 | ||
| Clinical applications for microRNAs in cancer | Q38065062 | ||
| Cancer control and prevention: nutrition and epigenetics | Q38107065 | ||
| Cancer development, progression, and therapy: an epigenetic overview. | Q38154977 | ||
| Epigenetic perspectives on cancer chemotherapy response | Q38209574 | ||
| DNA methylation and personalized medicine | Q38250428 | ||
| Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway | Q38477901 | ||
| MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer | Q38895915 | ||
| miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells | Q38905678 | ||
| rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression | Q38912510 | ||
| microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome | Q38944612 | ||
| Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance | Q38953995 | ||
| Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. | Q38985436 | ||
| The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer | Q39029645 | ||
| Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region | Q39029755 | ||
| MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. | Q39085254 | ||
| Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer | Q39358547 | ||
| Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells | Q39371337 | ||
| Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. | Q39399172 | ||
| TFAP2E-DKK4 and chemoresistance in colorectal cancer | Q39417929 | ||
| Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide | Q39430288 | ||
| Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer | Q39439833 | ||
| miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. | Q39459142 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. | Q39467047 | ||
| Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population. | Q39521815 | ||
| GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response | Q39522129 | ||
| MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma | Q39598696 | ||
| Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells | Q39634084 | ||
| Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo | Q39671100 | ||
| Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells | Q39757723 | ||
| Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells | Q40171616 | ||
| Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. | Q40246018 | ||
| Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells | Q40272840 | ||
| MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma | Q40293483 | ||
| Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. | Q40301419 | ||
| Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells | Q40339777 | ||
| Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide | Q40522471 | ||
| Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. | Q40550191 | ||
| Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. | Q41135362 | ||
| Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues | Q42971072 | ||
| The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients | Q43628592 | ||
| CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas | Q45009128 | ||
| Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients | Q45285546 | ||
| MGMT methylation: a marker of response to temozolomide in low-grade gliomas | Q48325983 | ||
| Exploring and explaining epigenetic effects. | Q52193311 | ||
| DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. | Q52913574 | ||
| Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. | Q53628631 | ||
| Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. | Q54322917 | ||
| The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. | Q54365633 | ||
| MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma | Q56828332 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 673-684 | |
| P577 | publication date | 2015-12-26 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Epigenetic alternations and cancer chemotherapy response | |
| P478 | volume | 77 |
| Q64103282 | Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers |
| Q89543466 | DNA methylation alterations as therapeutic prospects in thyroid cancer |
| Q93185455 | EDNRB isoform 3 confers Temozolomide resistance in A375 melanoma cells by modulating membrane potential, reactive oxygen species and mitochondrial Ca2 |
| Q39433158 | Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy |
| Q41587848 | Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1) |
| Q64101728 | Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study |
| Q38725944 | MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells |
| Q57475451 | Pharmacogenetic testing in oncology: a Brazilian perspective |
| Q52605047 | Stochastic tuning of gene expression enables cellular adaptation in the absence of pre-existing regulatory circuitry. |
Search more.